Skip to content
Disability, Medical Health Aged Care

Monash Expert: NDIS Independent Review

Monash University 2 mins read

The Independent Review into the National Disability Insurance Scheme report has been released.  

Available to comment:

Associate Professor Libby Callaway, Occupational Therapy Independent Living Stream Lead: Rehabilitation, Ageing and Independent Living (RAIL) Research Centre Research Affiliate: Monash University National Centre for Healthy Ageing. Voluntary President of the Australian Rehabilitation and Assistive Technology Association (ARATA)
Contact details: +61, (0) 421 356 359 or [email protected]
Read more of Associate Professor Callaway’s commentary at Monash Lens

  • How the NDIS works
  • The need for an effective and sustainable NDIS
  • Where to from here

The following can be attributed to Associate Professor Callaway:

“Key recommendations focus on four areas:

  • Developing a unified system of support for people with disability
  • Investing in markets and support systems that empower people with disability
  • Ensuring stewardship of the unified ecosystem
  • Focusing on a 5-year transition period. 

“There is agreement that the NDIS has become an oasis in the desert of disability services, and redirecting funding to the scheme has left large gaps in mainstream services and unintended losses of past programs that benefit people of all ages and abilities, like state-based aids and equipment libraries or independent living centres. For these reasons, the NDIS has really become the only funding scheme available for people with disability to access the services and supports that they need, including young children with signs of early developmental delays.

“The diversion of state funding into the NDIS has also put increasing pressure on other systems - particularly the health system but also the housing system and informal carer networks, like ageing family members. 

“We know there are growing hospital length of stay issues for people with the most complex needs who don’t have housing options to move to, and where the states used to support people with disability where a housing crisis occurred, like the unexpected death of an ageing parent providing support to their family member with disability, there are very limited options in this space now. I would like to think that the national cabinet agreements yesterday will in part address this but we await the detail to understand more.

“There has been a lot of media focus on fraudulent behaviour by providers, and at times participants, and it is also important to consider the role of the independent regulator of NDIS funded services – the NDIS Quality and Safeguards Commission. Whilst the NDIS funds services, supports and equipment for NDIS participants, the National Disability Insurance Agency and Dept of Social Services relies on the NDIS Quality and Safeguards Commission to provide regulatory oversight to the market. 

“Government has recently increased investment in the Commission to enhance market oversight, and this will be important to both demonstrate what good NDIS service provision looks like, as well as identify and rapidly address fraudulent provider behaviour. For example, twin pricing, where there is one, lower price for a product or service for people outside the NDIS and then a higher price for NDIS funded supports or services is an issue that needs to be urgently addressed.”

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or [email protected]

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 07:34
Monash University

Fish oil supplement halves serious cardiovascular events in patients on dialysis

A daily fish oil supplement has been shown to significantly reduce serious cardiovascular events in people receiving dialysis for kidney failure. The findings come from a major international clinical trial co-led in Australia by Monash Health and the School of Clinical Sciences at Monash University. The PISCES trial involved 1,228 participants across 26 dialysis sites in Australia and Canada. Results were presented at the American Society of Nephrology Kidney Week 2025 and published simultaneously in The New England Journal of Medicine. Participants who received four grams per day of fish oil, containing the natural active ingredients EPA and DHA, experienced…

  • Community, Medical Health Aged Care
  • 08/12/2025
  • 04:15
Save Our Sons Duchenne Foundation

Global Clinical Experts Gather in Sydney to Advance Adult Duchenne Muscular Dystrophy Care

Key Facts: Life expectancy for Australians living with DMD have increased from 18 for those borne before 1970, to around 30 today. As adult care remains fragmented and inconsistent between hospitals and States, the Symposium will develop global multi-disciplinary care recommendations.MEDIA RELEASE A world-first International Symposium dedicated toimproving multi-disciplinary clinical care for adults living with Duchenne muscular dystrophy (DMD) will take place in Sydney over the next three days. Hosted by the Save Our Sons Duchenne Foundation, the invitation-only event will bring together more than 35 of the world’s leading clinicians and researchers to develop the first multidisciplinary, global best-practice…

  • Contains:
  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.